Furthermore, a decrease of osteocalcin (OCN), a noncollagenous protein strictly correlated with bone turnover, was found in BM and peripheral blood serum of AML patients, especially those with adverse-risk disease.26 Notably, a reduced OCN level correlates to inferior overall survival, poor response to chemotherapy, and lower relapse-free survival in AML patients. This evidence concerns the gene BGLAP and acute myeloid leukemia.